Nanobiotix CEO’s Expansion Plans Target ‘Millions’ Of Patients
Nanobiotix’s Radio-Enhancer NBTXR3 Is Being Tested In Multiple Indications
Executive Summary
Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.